Role of @entity554 receptors in the prevention and treatment of XXXX .

@entity1 @entity172 @entity137 @entity4878 @entity0 @entity5 @entity19 @entity904 @entity2533 @entity1178 @entity8620 @entity35 @entity1968 @entity554
@entity4878 are @entity904 -related compounds that have been found to prevent @entity5 in animals and @entity1 . In this review, we discuss the role of @entity4878 and their receptors in the treatment and prevention of @entity0 . The @entity554 receptors are expressed in normal and malignant breast cells, and are critical for normal development. In breast cells, when bound by @entity554 hormones, these proteins regulate proliferation, apoptosis, and differentiation. The mechanism by which @entity4878 inhibit breast cell growth has not been completely elucidated, however, @entity4878 have been shown to affect multiple signal transduction pathways, including IGF-, @entity2533 -, and @entity1178 -dependent pathways. @entity4878 have also been shown to suppress the growth and prevent the development of @entity0 in animals. These agents suppress tumorigenesis in carcinogen-treated @entity35 and in @entity19 , and inhibit the growth of transplanted @entity0 . These promising preclinical results have provided the rationale to test @entity4878 in clinical trials for the treatment and prevention of @entity0 . Several @entity4878 , including all trans @entity1968 and @entity8620 , have been shown to have modest activity in the treatment of @entity0 , and these agents are now in clinical trials in combination with cytotoxic agents and anti- @entity172 . Another @entity554 , 4-HPR, is currently being tested in a @entity1 @entity5 prevention trial. Preliminary results suggest that 4-HPR may suppress @entity0 development in premenopausal @entity1 . Future clinical trials will focus on testing new synthetic @entity4878 that have reduced @entity137 and enhanced therapeutic and preventive efficacy.
